R&D
Pipeline
Development of Pharmabiotics(LBP)
| Indication | Indication | Discovery | Pre-clinical | Clinical trial | Status | |||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||||
 |
Major Depression Disorder | HEMP-001 (Candidate substance H20-01) |
|
US FDA Clinical 2a IND Approved |
||||
| Autism Spectrum Disorder | TBD |
|
||||||
 |
Atopic Dermatitis | HEMP-001 (Candidate substance H20-01) |
|
|||||
 |
Low Anterior Resection Syndrome |
HEMP-002 (Candidate substance H1036) |
|
AUS HREC Clinical 2a Approved |
||||
| Cancer-Induced Diarrhea |
|
|||||||
 |
Chronic Obstructive Pulmonary Disease |
HEMP-003 (Candidate substance H792) |
|
|||||
| Non-Alcholic Fatty Liver Disease |
TBD |
|
||||||
| Type 2 Diabetes | TBD |
|
||||||
 |
Constipation (in Children) | TBD |
|
|||||
Development of Probiotics
| Product name | Partner company | Contract | Product development | Trial production | Commercialization |
|---|---|---|---|---|---|
| BWI Immunity | A** |
|
|||
| Zeta Bio (B-active) | C** |
|
|||
| E. Faecium HAC233 | L** |
|
|||
| MyLAB by NUTRILITE | A** |
|
|||
| Customized lactic acid bacteria | Our company’s new brand |
|
|||
